Table 3. Univariate and multivariate analyses for relapse-free survival.
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| Age (< 40 yr) | 2.393 | 1.494–3.834 | < 0.001 | 2.796 | 1.510–5.177 | 0.001 | |
| Menopausal status (premenopausal) | 0.827 | 0.542–1.263 | 0.379 | 0.591 | 0.552–1.630 | 0.063 | |
| ER and/or PR (positive) | 0.309 | 0.202–0.417 | < 0.001 | 0.489 | 0.297–0.804 | 0.005 | |
| HER2 (positive) | 1.424 | 0.847–2.395 | 0.183 | 0.949 | 0.552–1.630 | 0.849 | |
| AR (≥ 35%) | 0.254 | 0.164–0.394 | < 0.001 | 0.430 | 0.260–0.709 | 0.001 | |
| P stage (II, III) | 6.225 | 3.305–11.723 | < 0.001 | 5.397 | 2.859–10.189 | < 0.001 | |
| Breast cancer subtypes | < 0.001 | - | - | - | |||
| Luminal A | 0.097 | 0.045–0.211 | < 0.001 | ||||
| Luminal B (HER2−) | 0.391 | 0.235–0.650 | < 0.001 | ||||
| Luminal B (HER2+) | 0.468 | 0.224–1.055 | 0.068 | ||||
| HER2-positive | 0.550 | 0.270–1.119 | 0.099 | ||||
| TNBC | 1.000 | - | - | ||||
HR = hazard ratio; CI = confidence interval; ER = estrogen receptor; PR = progesterone receptor; AR = androgen receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.